Upon intravenous infusion, more than 80% of MSCs are entrapped in the lungs, and only less than 1% of MSCs are detected in the acute ischemic heart or brain (Lee et al., 2009; Toma et al., 2009) .
and gentamicin/amphotericin-B (GA).
B. Optimization of blocking antibody concentrations and cell adhesion assay 1. Coat 24-well plates with 10 μg/ml fibronectin (diluting in sterile HBSS or PBS solutions) or 0.4-1 μg/ml vitronectin (diluting in sterile water) for 1 h at room temperature.
2. Remove fibronectin or vitronectin buffer without washing, air dry for 1-2 h in a hood.
3. Block the plates with 3% BSA in PBS for 1 h at 37 °C.
4. Gently wash the plates with PBS once, air dry in a hood.
5. Use 3% BSA in PBS alone-coated wells as a negative control. 12. Centrifuge non-adherent cells at 400 x g, 5 min.
13. Count the non-adherent cells with a hemocytometer.
14. Photograph the DiI-labelled hMSCs in attachment by fluorescence microscopy.
15. The experiment must be performed in quadruplicate for each variable.
C. hMSCs attachment to endothelial cells 2. The lowest concentrations of the blocking antibodies that achieved maximum inhibition to hMSCs attachment were chosen for experiments: integrin β1 at 4 μg/ml, integrin α5 at 10 μg/ml, and integrin αVβ3 at 5 μg/ml.
